CMS stance on carotid stenting ignores science, kills innovation, SCAI doc argues

04/29/2013 | CardiovascularBusiness.com

Carotid stent therapy has been shown to be as effective as surgery in low-risk asymptomatic patients, yet CMS has upheld a 25-year-old noncoverage stance, without explanation, writes Dr. Christopher White, SCAI's immediate past president. Many observers believe CMS' position is the result of "turf battles," which have permitted the agency to disregard scientific results and to stifle medical innovation, Dr. White writes. The result, he says, is that patients are unable to opt for the treatment that may be best for them.

View Full Article in:

CardiovascularBusiness.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI